However, if your genetic profile suggests slower GLP-1 signaling efficiency, your provider may consider that hormonal fluctuations could amplify variability in your response
Semaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist that mimics a hormone to increase insulin secretion, slow gastric emptying, and reduce appetite
This can be for several reasons, including how the patient tolerates the medications side effects and their clinical responses to the treatment. A typical dosage chart increases until the goal dose is met Dosage charts show patients the trajectory of their progress
Most researchers report no noticeable potency issues at the 5-week mark, but conservative protocols suggest using the vial within 4 weeks and discarding any remainder
But dose is one variable in a larger system
Inquire now for a price list tailored to your needs